Rare disease biotech Bio Blast Pharma sets terms for $40 million IPO

By Renaissance Capital,

Shutterstock photo

Bio Blast Pharma, a clinical-stage biotech developing treatments for rare and ultra-rare genetic diseases, announced terms for its IPO on Tuesday. The Tel Aviv, Israel-based company plans to raise $40 million by offering 3.3 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Bio Blast would command a fully diluted market value of $178 million.

Bio Blast Pharma, which was founded in 2012, plans to list on the NASDAQ under the symbol ORPN. Oppenheimer and Roth Capital are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: ORPN

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by BankRate.com